Last Updated : January 29, 2025
Details
Generic Name:
glofitamab
Project Status:
Pending
Therapeutic Area:
Relapsed or refractory diffuse large B-cell lymphoma
Manufacturer:
Hoffmann-La Roche Limited
Call for patient/clinician input open:
Brand Name:
Columvi
Project Line:
Reimbursement Review
Project Number:
PC0406-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Columvi (glofitamab for injection) in combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Columvi (glofitamab for injection) in combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 29, 2025